TriangleNCT00976248 · OUTCOME
Time to Progression With Single Agent RAD001 Therapy in Previously Untreated WM.
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- Full Range
- Time frame
- End of Treatment, an average of 16 months
What was measured
Progression is defined as a 25% increase in serum IgM from the lowest attained response value or progression of clinically significant disease related symptoms.
Analysis population: 13 participants were excluded from this analysis due to treatment and follow-up ending prior to progression.
Groups in this outcome
RAD001
RAD001, oral, 10 mg, daily RAD001: Taken orally once a day
| Group | Source count |
|---|---|
| RAD001 | 20 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| RAD001 | 21 | Not reported | 1 | 64 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1
- upper Limit
- 64
- value
- 21
- denoms
- counts
- group Id
- OG000
- value
- 20
- units
- Participants
- description
- Progression is defined as a 25% increase in serum IgM from the lowest attained response value or progression of clinically significant disease related symptoms.
- dispersion Type
- Full Range
- groups
- description
- RAD001, oral, 10 mg, daily RAD001: Taken orally once a day
- id
- OG000
- title
- RAD001
- param Type
- MEDIAN
- population Description
- 13 participants were excluded from this analysis due to treatment and follow-up ending prior to progression.
- reporting Status
- POSTED
- time Frame
- End of Treatment, an average of 16 months
- title
- Time to Progression With Single Agent RAD001 Therapy in Previously Untreated WM.
- type
- PRIMARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice